- Home
- KRP vs EYPT Comparison
KRP vs EYPT Comparison
Compare KRP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRP | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KRP | EYPT |
|---|---|---|
| Price | $14.50 | $13.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.33 | ★ $31.80 |
| AVG Volume (30 Days) | 666.9K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $333,830,000.00 | $7,539,000.00 |
| Revenue This Year | $6.88 | N/A |
| Revenue Next Year | N/A | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $11.31 | $9.41 |
| 52 Week High | $15.80 | $19.11 |
Technical Indicators
Market Signals| Indicator | KRP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 55.34 |
| Support Level | $14.10 | $12.01 |
| Resistance Level | $14.95 | $14.52 |
| Average True Range (ATR) | 0.27 | 1.05 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 7.20 | 51.38 |
Price Performance
Historical ComparisonAbout KRP Kimbell Royalty Partners
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.